Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 71, Issue 2, 1997, Pages 173-179

  Meden, Harald ^a   Kuhn, Walter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

c erbB 2; HER2 neu; oncogene; ovarian cancer; p185; prognosis

Indexed keywords

MONOCLONAL ANTIBODY;

CONFERENCE PAPER; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031080971     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(96)02630-9     Document Type: Conference Paper

References (36)

1. [1] Sorbe B, Frankendal B, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 1982; 59: 576-582.
2. [2] Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-420.
3. [3] Malkasian GD jr, Melton LJ, O'Brien PC, Greene MH. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 1984; 149: 274-284.
4. [4] Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 1985; 65: 264-270.
5. [5] Alitalo K, Schwab M. Oncogene amplification in tumor cell. Adv Cancer Res 1986; 47: 235-281.
6. [6] Bishop JM. The molecular genetics of cancer. Science 1987; 235: 305-3.
7. [7] Münzel P, Marx D, Köchel H, Schauer A, Bock KW. Genomic alterations of the c-myc proto-oncogene in relation to the overexpression of c-erbB-2 and ki-67 in human breast cancer and cervix carcinomas. J Cancer Res Clin Oncol 1991; 117: 603-607.
8. [8] Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
9. [9] Coussens L, Yang-Feng TL, Liao YC et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1185.
10. [10] Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-releated protein. Nature 1986; 319: 226-230.
11. [11] Yamamoto T, Shantard I, Akiyama T, Semba J, Nomura N, Miyajina N, Saito T, Toyoshima K. Am erb-B-related gene c-erbB-2 encodes a possible receptor protein similar to the epidermanl growth factor receptor. Nature 1986; 319: 230-234.
12. [12] King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974-976.
13. [13] Slamon DJ, Clark GM, Wong SG, Levin WJ, Ulrich A, McGuire WL. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
14. [14] Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlation with gene amplification. Lancet 1987; 2: 68-72.
15. [15] Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NR. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status und nuclear grading. Cancer Res 1988; 48: 1238-1243.
16. [16] van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. NEU-protein overexpression in breast cancer. N Engl J Med 1988; 319: 1239-1245.
17. [17] Marx D, Schauer A, Reiche C et al. c-erbB-2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 1990; 116: 15-20.
18. [18] Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W, Schauer A. Overexpression of the oncogene c-erbB-2 in primary ovarian cancer. Evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994; 13: 45-53.
19. [19] Berchuck A, Kamel A, Whitaker R et al. Overexpression of HER-1/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
20. [20] Haldane JS, Hird V, Hughes CM, Gullick WJ. C-erbB-2 oncogene expression in ovarian cancer. H Pathol 1990; 162: 231-237.
21. [21] Meden H, Marx D, Fattahi A, Rath W, Kron M, Wuttke W, Schauer A, Kuhn W. Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. J Cancer Res Clin Oncol 1994; 120: 378-381.
22. [22] Akiyama T, Saito T, Ogawara H, Toyoshima K, Yamamoto T. Tumor promotor and epidermal growth factor stimulate phosphorylation of the c-erbB-2 gene product in MKN-7 human adenocarcinoma cells. Mol Cell Biol 1988; 8: 1019-1026.
23. [23] Nicholson S, Sainsbury JRC, Halcrow P et al. Expression of EGF receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989; 1: 182-185.
24. [24] Meden H, Marx D, Raab T, Kron M, Schauer A, Kuhn W. EGF-R and overexpression of the oncogene c-erbB-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynecol 1995; 21: 167-178.
25. [25] Bauknecht T, Janz I, Kohler M, Pfleiderer A. Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F). Med Oncol Tumor Pharmacother 1989; 6: 121-127.
26. [26] Battaglia F, Scambia G, Benedetti Panici P, Baiocchi G, Perrone L, Jacobelli Manusco S. Epidermal growth factor receptor expression in gynecological malignancies. Gynecol Obstet Invest 1989; 27: 42-44.
27. [27] Rodenburg CJ, van der Burg ME, Berns PM, van der Gaast A, van Putten WLJ, Brussée R, Foekens JA, Klijn JGM, Henzen-Logmans S. The prognostic significance of epidermal growth factor (EGF) receptors measured by immunohistochemistry in advanced ovarian cancer. Proc 81st Ann Meeting Am Ass Cancer Res 1990; 31: 222.
28. [28] van der Burg ME, Henzen-Logmans SC, Foekens JA, Berns EM, Rodenburg CJ, van Putten WL, Klijn JG. The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer 1993; 29: 1951-1957.
29. [29] Foekens JA, van Putten WLJ, Portengen H, Rodenburg CJ, Reubl JC, Berns PMJJ, Henzen-Logmans SC, van der Burg MEL, Alexieva-Figusch J, Klijn JGM. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R). Insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer. J Steroid Biochem Molec Biol 1990; 37: 815-821.
30. [30] Zabrecky JR, Lam T, McKenzie SJ, Carney W. The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells. SK-BR-3. J Biol Chemistry 1991; 266: 1716-1720.
31. [31] Ozawa S, Ueda M, Ando N, Osahiko A, Shimizu N. High incidence of EGF-receptor hyperproduction in esophageal squamouscell carcinomas. Int J Cancer 1987; 39: 333-337.
32. [32] Moroni MC, Willingham MC, Bequinot L. EGFR anti-sense RNA blocks expression of epidermal-growth-factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J Biol Chem 1992; 267: 2714-2722.
33. [33] Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich, Sela M, Yarden Y. Tumorinhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast-cancer cells. Cancer Res 1992; 52: 2580-2589.
34. [34] Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 1988; 2: 387-394.
35. [35] Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ulrich A. p185 HER-2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9: 1165-1172.
36. [36] Baselga J, Tripathy D, Mendelsohn J et al.. Phase II study of recombinant human anti-HER2 monoclonal antibody (rhuMAb HER2) in stage IV breast cancer (BC): HER2-shedding dependent pharmacokinetics and antitumor activity. Proc of ASCO 1995; 12: 103.